MDT-AP-0045
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- os_event
- false
- age_years
- 5
- sex
- M
- new_clusters
- C2
- umap1_2d
- 2.298921662
- umap2_2d
- 1.806863316
- umap1_3d
- -0.495337053
- umap2_3d
- -2.456470104
- umap3_3d
- -2.273647171
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.590
- MYC_TARGETS_V1+0.410
- G2M_CHECKPOINT+0.330
- UNFOLDED_PROTEIN_RESPONSE+0.310
- PEROXISOME+0.290
- E2F_TARGETS+0.270
- PANCREAS_BETA_CELLS+0.250
- HEDGEHOG_SIGNALING+0.240
- DNA_REPAIR+0.230
- MITOTIC_SPINDLE+0.230
Top 10 suppressed
- KRAS_SIGNALING_UP-0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.330
- ALLOGRAFT_REJECTION-0.320
- COMPLEMENT-0.300
- IL6_JAK_STAT3_SIGNALING-0.290
- INFLAMMATORY_RESPONSE-0.290
- COAGULATION-0.250
- MYOGENESIS-0.250
- TNFA_SIGNALING_VIA_NFKB-0.250
- XENOBIOTIC_METABOLISM-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-70-6723-01A-11R-1820-07 | — | cohortSQ2 | 0.829 |
| 2 | 004064de-0e10-491d-b3d8-bc628a8f70a8 | — | — | 0.822 |
| 3 | TCGA-BH-A18L-01A-32R-A12D-07 | — | B | 0.820 |
| 4 | A85A0E3A-2CB9-40EB-80E9-125EC137151B | — | — | 0.820 |
| 5 | E3A67B7B-7427-4C11-912B-166451072767 | — | — | 0.817 |
| 6 | 93B9C99A-08DD-4F78-9CF5-C59A01605C9D | — | — | 0.815 |
| 7 | SRR15030853 | — | — | 0.811 |
| 8 | 4D9EF242-9F58-4681-ADCF-556E05932931 | — | — | 0.809 |
| 9 | MDT-AP-0167 | Med | Medulloblastoma | 0.808 |
| 10 | SRR12202462 | — | — | 0.804 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.590 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.410 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.310 | Idelalisib | — uncovered |
| PEROXISOME | 0.290 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.270 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.240 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.230 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.190 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.180 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.160 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.130 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |